Blog
Vertex Presents New CASGEVY® Data in Patients 5-11 Years and Announces Plan for Global Regulatory Submissions
On December 6, 2025, Vertex Pharmaceuticals Inc. (“Vertex”) announced data from several studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel), including, for the first time, clinical data from studies in children ages 5-11 years….
By: Goodwin